Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration

J Toxicol Sci. 1996 Dec;21(5):309-16. doi: 10.2131/jts.21.5_309.

Authors

Y Sugiyama¹, T Iwatsubo, K Ueda, K Ito

Affiliation

¹ Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Tokyo, Japan.

PMID: 9035043
DOI: 10.2131/jts.21.5_309

No abstract available

Publication types

Review

MeSH terms

Drug Design*
Drug Interactions
Drug-Related Side Effects and Adverse Reactions*
Humans
Pharmaceutical Preparations / metabolism*
Pharmacokinetics*
Product Surveillance, Postmarketing
Risk Assessment

Substances

Pharmaceutical Preparations